0.19

4.19% -0.0083

After Hours: .19

Lyra Therapeutics Inc (LYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Lyra Therapeutics Inc stock is traded at $0.19, with a volume of 1.34M. It is down -4.19% in the last 24 hours and down -23.97% over the past month. Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Previous Close:

$0.1983

Open:

$0.1999

24h Volume:

1.34M

Relative Volume:

0.93

Market Cap:

$12.98M

Revenue:

$1.56M

Net Income/Loss:

$-62.68M

P/E Ratio:

-0.1218

EPS:

-1.56

Net Cash Flow:

$-64.35M

1W Performance:

+6.74%

1M Performance:

-23.97%

6M Performance:

-41.63%

1Y Performance:

-94.31%

1-Day Range:

$0.1839

$0.207

1-Week Range:

$0.1745

$0.207

52-Week Range:

$0.1625

$6.79

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name

Lyra Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-373-4600

Address

480 ARSENAL WAY, WATERTOWN, MA

Employee

Twitter

@LyraTx

Next Earnings Date

2024-11-05

Latest SEC Filings

LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYRA Lyra Therapeutics Inc	0.19	12.98M	1.56M	-62.68M	-64.35M	-1.56
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral
May-07-24	Downgrade	Jefferies	Buy → Hold
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy
Aug-31-23	Initiated	H.C. Wainwright	Buy
May-24-22	Initiated	Cantor Fitzgerald	Overweight
May-26-20	Initiated	BTIG Research	Buy
May-26-20	Initiated	BofA/Merrill	Buy
May-26-20	Initiated	Jefferies	Buy
May-26-20	Initiated	William Blair	Outperform

View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

Nov 26, 2024

Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World

Nov 26, 2024

Nov 18, 2024

William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World

Nov 18, 2024

HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World

Nov 18, 2024

Nov 14, 2024

Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa

Nov 13, 2024

Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India

Nov 13, 2024